Drug × Cancer matrix

Each row is a drug, each column a cancer subtype. Cells show the strongest known association for that drug in that cancer: approved clinical trial or blank. The repositionable flag means the drug appears as a synthetic-lethal repositioning candidate in cansar; it’s gene-level, not cancer-level.

Cancer key
GBM — Glioblastoma (CNS astrocytoma grade IV) LUAD — Lung adenocarcinoma SCLC — Small cell lung carcinoma LUSC — Lung squamous cell carcinoma OAC — Oesophageal adenocarcinoma OSCC — Oesophageal squamous cell carcinoma PDAC — Pancreatic ductal adenocarcinoma
Clear
Showing 100 of 853 matching drugs for ESR1 — including drugs targeting any of its 145 synthetic-lethal partners , sorted by total cancer coverage.
Drug Target Relationship GBM LUAD SCLC LUSC OAC OSCC PDAC Reposition #cancers
alendronate, etidronate, ibandronate, risedronate, raloxifene ESR1 Direct 2
eft226, sotorasib, fulvestrant, abemaciclib, trastuzumab ESR1 Direct 2
gefitinib, fulvestrant, erlotinib ESR1 Direct 2
sy-5609, fulvestrant, gemcitabine, nab-paclitaxel ESR1 Direct 2
blu-222, carboplatin, ribociclib, fulvestrant ESR1 Direct 1
genistein, erlotinib hydrochloride, gemcitabine hydrochloride ESR1 Direct 1
levonorgestrel, metformin ESR1 Direct 1
omeprazole, melatonin ESR1 Direct 1
pf-07220060, letrozole, fulvestrant, midazolam, enzalutamide ESR1 Direct 1
tamoxifen, etoposide ESR1 Direct 1
allylestrenol ESR1 Direct yes 0
bazedoxifene ESR1 Direct yes 0
bazedoxifene acetate ESR1 Direct yes 0
clomiphene ESR1 Direct yes 0
clomiphene citrate ESR1 Direct yes 0
cyclofenil ESR1 Direct yes 0
danazol ESR1 Direct yes 0
dienestrol ESR1 Direct yes 0
diethylstilbestrol ESR1 Direct yes 0
diethylstilbestrol diphosphate ESR1 Direct yes 0
estetrol ESR1 Direct yes 0
estradiol ESR1 Direct yes 0
estradiol acetate ESR1 Direct yes 0
estradiol benzoate ESR1 Direct yes 0
estradiol cypionate ESR1 Direct yes 0
estradiol valerate ESR1 Direct yes 0
estriol ESR1 Direct yes 0
estrone ESR1 Direct yes 0
estrone sulfuric acid ESR1 Direct yes 0
estropipate ESR1 Direct yes 0
ethinyl estradiol ESR1 Direct yes 0
fulvestrant ESR1 Direct yes 0
lasofoxifene ESR1 Direct yes 0
mestranol ESR1 Direct yes 0
ospemifene ESR1 Direct yes 0
polyestradiol phosphate ESR1 Direct yes 0
quinestrol ESR1 Direct yes 0
tamoxifen ESR1 Direct yes 0
tamoxifen citrate ESR1 Direct yes 0
toremifene ESR1 Direct yes 0
toremifene citrate ESR1 Direct yes 0
olaparib PARP1 SSL via PARP1 yes 1
sunitinib KIT SSL via KIT yes 5
sunitinib PDGFRB SSL via PDGFRB yes 5
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab KIT SSL via KIT 4
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab PDGFRB SSL via PDGFRB 4
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab RAF1 SSL via RAF1 4
regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) KIT SSL via KIT 4
regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) PDGFRB SSL via PDGFRB 4
regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) RAF1 SSL via RAF1 4
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib CDK4 SSL via CDK4 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib ERBB4 SSL via ERBB4 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib KIT SSL via KIT 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib MAP2K1 SSL via MAP2K1 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib MAPK14 SSL via MAPK14 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib PDGFRB SSL via PDGFRB 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib RAF1 SSL via RAF1 3
afatinib ERBB4 SSL via ERBB4 yes 3
dec-205/ny-eso-1 fusion protein cdx-1401, laboratory biomarker analysis, pharmacological study, sirolimus MTOR SSL via MTOR 3
futibatinib, pembrolizumab, cisplatin, 5-fu, oxaliplatin, leucovorin, levoleucovorin, irinotecan TOP1 SSL via TOP1 3
lurbinectedin, irinotecan TOP1 SSL via TOP1 3
mrtx849, pembrolizumab, cetuximab, afatinib ERBB4 SSL via ERBB4 3
nivolumab or pembrolizumab (dependent upon approved indication), metformin, rosiglitazone PPARD SSL via PPARD 3
nivolumab or pembrolizumab (dependent upon approved indication), metformin, rosiglitazone PPARG SSL via PPARG 3
pembrolizumab, belzutifan, lenvatinib KIT SSL via KIT 3
abemaciclib CDK4 SSL via CDK4 yes 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel ERBB4 SSL via ERBB4 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel INSR SSL via INSR 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel MAP2K1 SSL via MAP2K1 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel RAF1 SSL via RAF1 2
alvocidib, paclitaxel CDK4 SSL via CDK4 2
apatinib, irinotecan TOP1 SSL via TOP1 2
asp2138, pembrolizumab, oxaliplatin, leucovorin, fluorouracil, ramucirumab, paclitaxel, irinotecan TOP1 SSL via TOP1 2
asp3082, cetuximab, leucovorin, oxaplatin, fluorouracil, irinotecan, nanoparticle albumin-bound-paclitaxel, gemcitabine TOP1 SSL via TOP1 2
avapritinib KIT SSL via KIT yes 2
bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment KIT SSL via KIT 2
bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment MAPK14 SSL via MAPK14 2
bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment PDGFRB SSL via PDGFRB 2
binimetinib, biopsy, biospecimen collection, bone scan, computed tomography, magnetic resonance imaging, palbociclib CDK4 SSL via CDK4 2
binimetinib, biopsy, biospecimen collection, bone scan, computed tomography, magnetic resonance imaging, palbociclib MAP2K1 SSL via MAP2K1 2
bryostatin 1, paclitaxel CCND1 SSL via CCND1 2
bryostatin 1, paclitaxel PRKCA SSL via PRKCA 2
cetuximab, cisplatin, irinotecan, radiation therapy, surgery TOP1 SSL via TOP1 2
cft1946, trametinib, cetuximab MAP2K1 SSL via MAP2K1 2
cixutumumab, everolimus, laboratory biomarker analysis, octreotide acetate, pharmacological study MTOR SSL via MTOR 2
cobimetinib, mehd7945a MAP2K1 SSL via MAP2K1 2
eft226, sotorasib, fulvestrant, abemaciclib, trastuzumab CDK4 SSL via CDK4 2
entrectinib, entrectinib, alectinib, atezolizumab, ipatasertib, trastuzumab emtansine, idasanutlin, inavolisib, belvarafenib, pralsetinib, gdc-6036, camonsertib JAK2 SSL via JAK2 2
entrectinib, entrectinib, alectinib, atezolizumab, ipatasertib, trastuzumab emtansine, idasanutlin, inavolisib, belvarafenib, pralsetinib, gdc-6036, camonsertib PDGFRB SSL via PDGFRB 2
everolimus MTOR SSL via MTOR yes 2
fluorouracil, irinotecan hydrochloride, leucovorin calcium, vorinostat, pharmacological study HDAC3 SSL via HDAC3 2
gi-101, pembrolizumab (keytruda®), lenvatinib, local radiotherapy, gi-101a KIT SSL via KIT 2
inbrx-109, carboplatin, cisplatin, pemetrexed, 5-fluorouracil, irinotecan, temozolomide TOP1 SSL via TOP1 2
ioa-244, avelumab injection, pemetrexed, cisplatin, ruxolitinib JAK2 SSL via JAK2 2
irinotecan, capecitabine TOP1 SSL via TOP1 2
irinotecan, docetaxel TOP1 SSL via TOP1 2
jab-3312, binimetinib, pembrolizumab, sotorasib, osimertinib MAP2K1 SSL via MAP2K1 2
ksq-001ex, interleukin-2, cyclophosphamide, fludarabine POLA1 SSL via POLA1 2
lenvatinib, pembrolizumab KIT SSL via KIT 2
lenvatinib, pembrolizumab, hyperpolarized 13c-pyruvate KIT SSL via KIT 2
Approval data manually curated from National Cancer Institute and Drugs@FDA. Clinical trials from ClinicalTrials.gov. Repositionable list from cansar.ai.